{"id":10657,"date":"2019-11-12T11:18:55","date_gmt":"2019-11-12T05:48:55","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=10657"},"modified":"2026-07-23T15:54:29","modified_gmt":"2026-07-23T10:24:29","slug":"car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/","title":{"rendered":"CAR T Cell Therapy: Autolus Presents Data on AUT06NG"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"71\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Autolus-Therapeutics-Logo-Roots.webp\" alt=\"Autolus Logo\" class=\"wp-image-17486\" style=\"object-fit:contain;width:300px;height:72px\"\/><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.autolus.com\/innovation\/pipeline-products\/our-products\/\">Autolus<\/a><a href=\"https:\/\/www.autolus.com\/\"> Therapeutics<\/a>, a clinical-stage <a href=\"https:\/\/www.rootsanalysis.com\/reports\/biopharmaceutical-contract-manufacturing-market\/250.html\">biologics contract manufacturing<\/a> company developing next-generation programmed T cell therapies for the treatment of cancer, presented pre-clinical data on AUTO6NG, the company\u2019s next-generation GD2-targeting CAR T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What did the results highlight:<\/strong>&nbsp;The results demonstrated the utility of three modules added to the clinically active and validated AUTO6 GD-2 targeting CAR that not only improves CAR T <a href=\"https:\/\/www.rootsanalysis.com\/blog\/car-t-cell-therapies-addressing-key-unmet\/\">cell therapy<\/a> persistence but also combats the immunosuppressive environment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What is <a href=\"https:\/\/www.autolus.com\/technology\/overview\">AUTO6NG<\/a>:&nbsp;<\/strong>AUTO6NG is a next-generation programmed T cell product candidate in pre-clinical development.&nbsp; AUTO6NG builds on preliminary proof of concept data from AUTO6, a <a href=\"https:\/\/www.rootsanalysis.com\/reports\/car-t-cell-therapy-market\/269.html\">CAR T cell therapy market<\/a> product in clinical development for the treatment of neuroblastoma, which can target GD2-expressing cancers with a chimeric antigen receptor.&nbsp; AUTO6NG incorporates additional cell programming modules to augment its functions by extending persistence and rendering modified T-cells resistant to immune inhibition.&nbsp; With the enhanced properties of AUTO6NG, it may be suitable for the treatment of GD2-expressing solid tumors, including neuroblastoma, osteosarcoma, melanoma, small cell lung cancer, and soft tissue sarcoma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What is <a href=\"https:\/\/www.sciencedirect.com\/topics\/biochemistry-genetics-and-molecular-biology\/gd2\">GD2<\/a>: <\/strong>GD2 is a&nbsp;<a title=\"Learn more about Glycolipid from ScienceDirect's AI-generated Topic Pages\" href=\"https:\/\/www.sciencedirect.com\/topics\/biochemistry-genetics-and-molecular-biology\/glycolipid\">glycolipid<\/a>&nbsp;that is most commonly expressed in the majority of neuroblastoma tumors, thus representing a good diagnostic marker and therapeutic target. It&nbsp;is present on a variety of solid tumors in addition to neuroblastoma, including osteosarcoma, retinoblastoma, some soft tissue sarcomas, brain tumors, mesenchymal stem cells, and cancer stem cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How popular is GD2 in the CAR T Therapy Pipeline<\/strong>?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">GD2 is the second most popular target of CAR-T therapies being developed for solid tumors. Presently, close to 20 GD2 targeting therapies are in clinical development by <a href=\"https:\/\/www.rootsanalysis.com\/key-insights\/5-leading-car-t-cell-therapy-companies.html\">CAR T cell therapy companies<\/a> for the treatment of various solid tumors, including neuroblastoma, glioma, cervical cancer, sarcoma, osteosarcoma, and melanoma. Here is the distribution of the T-cell therapies pipeline by targets:<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"636\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-1024x636.webp\" alt=\"Based on analysis by Roots, T-Cell Pipeline Distribution by Targets\" class=\"wp-image-17487\" style=\"object-fit:contain;width:800px;height:498px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-1024x636.webp 1024w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-300x186.webp 300w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-768x477.webp 768w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-1536x953.webp 1536w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots-200x125.webp 200w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Distribution-of-the-T-Cell-Therapies-Pipeline-by-targets-Roots.webp 1716w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">For more insights about the T-Cell therapies market, you can also download the&nbsp;<a href=\"https:\/\/www.rootsanalysis.com\/reports\/car-t-therapies-market-2nd-edition-2019-2030\/request-sample.html\">SAMPLE REPORT<\/a>&nbsp;on T Cell therapies by Roots Analysis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Autolus Therapeutics, a clinical-stage biologics contract manufacturing company developing next-generation programmed T cell therapies for the treatment of cancer, presented pre-clinical data on AUTO6NG, the company\u2019s next-generation GD2-targeting CAR T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). What did the results highlight:&nbsp;The results demonstrated the utility of [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":17023,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[161,162],"class_list":["post-10657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cell-therapies","tag-car-t","tag-t-cell"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG<\/title>\n<meta name=\"description\" content=\"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG\" \/>\n<meta property=\"og:description\" content=\"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-12T05:48:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T10:24:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"150\" \/>\n\t<meta property=\"og:image:height\" content=\"102\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Gaurav Chaudhary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gaurav Chaudhary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/\"},\"author\":{\"name\":\"Gaurav Chaudhary\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\"},\"headline\":\"CAR T Cell Therapy: Autolus Presents Data on AUT06NG\",\"datePublished\":\"2019-11-12T05:48:55+00:00\",\"dateModified\":\"2026-07-23T10:24:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/\"},\"wordCount\":360,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_DNA.webp\",\"keywords\":[\"CAR-T\",\"T-Cell\"],\"articleSection\":[\"Cell Therapies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/\",\"name\":\"Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_DNA.webp\",\"datePublished\":\"2019-11-12T05:48:55+00:00\",\"dateModified\":\"2026-07-23T10:24:29+00:00\",\"description\":\"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_DNA.webp\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_DNA.webp\",\"width\":150,\"height\":102,\"caption\":\"This is a feature image for blog article CAR-T Pipeline at Roots Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAR T Cell Therapy: Autolus Presents Data on AUT06NG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\",\"name\":\"Gaurav Chaudhary\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"caption\":\"Gaurav Chaudhary\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG","description":"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG","og_description":"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies","og_url":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2019-11-12T05:48:55+00:00","article_modified_time":"2026-07-23T10:24:29+00:00","og_image":[{"width":150,"height":102,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp","type":"image\/webp"}],"author":"Gaurav Chaudhary","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Gaurav Chaudhary","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/"},"author":{"name":"Gaurav Chaudhary","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc"},"headline":"CAR T Cell Therapy: Autolus Presents Data on AUT06NG","datePublished":"2019-11-12T05:48:55+00:00","dateModified":"2026-07-23T10:24:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/"},"wordCount":360,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp","keywords":["CAR-T","T-Cell"],"articleSection":["Cell Therapies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/","url":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/","name":"Autolus Unveils Preclinical Data on GD2-Targeting AUT06NG","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp","datePublished":"2019-11-12T05:48:55+00:00","dateModified":"2026-07-23T10:24:29+00:00","description":"According to Roots Analysis, close to 20 GD2 targeting therapies are in clinical development by CAR T cell therapy companies","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_DNA.webp","width":150,"height":102,"caption":"This is a feature image for blog article CAR-T Pipeline at Roots Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/car-t-pipeline-update-autolus-therapeutics-presents-preclinical-data-on-aut06ng\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"CAR T Cell Therapy: Autolus Presents Data on AUT06NG"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc","name":"Gaurav Chaudhary","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","caption":"Gaurav Chaudhary"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=10657"}],"version-history":[{"count":6,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10657\/revisions"}],"predecessor-version":[{"id":22362,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10657\/revisions\/22362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/17023"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=10657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=10657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=10657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}